Lymphangioleiomyomatosis: From Genetics to Management
Seminars in Respiratory and Critical Care Medicine · 06.11.2026
DOI: 10.1055/a-2991-9733 ↗Kurz gefasst
Fachartikel in der Zeitschrift Seminars in Respiratory and Critical Care Medicine, online erschienen am 06.11.2026. Verfasst von Spyros A Papiris und 11 weiteren Autor:innen. Beteiligte Einrichtung: Athens Medical School, National and Kapodistrian University of Athens, Attica, Greece, Athens. Die Arbeit nennt 268 Literaturangaben.
Abstract (Originalsprache)
Lymphangioleiomyomatosis (LAM) is a rare multisystem disease that exemplifies how sustained investigation can transform both biological understanding and clinical management. LAM is diagnosed almost exclusively in women, typically during the reproductive years, consistent with an important role for hormonal influences in disease activity. The disease is characterized by diffuse cystic lung remodeling that can lead to progressive loss of lung function and, in severe cases, respiratory failure. Once viewed primarily as an unusual smooth muscle-like proliferation, LAM is now considered a low-grade metastasizing neoplasm characterized by heterogeneous disease-cell states that contribute to remodeling of the lung parenchyma and interact dynamically with stromal, lymphatic, immune, metabolic, and hormonal cues. Although the anatomical origin of LAM cells remains debated and continues to be an active area of research, sporadic and tuberous sclerosis complex-associated LAM (S-LAM and TSC-LAM, respectively) share a central molecular mechanism: biallelic inactivation of TSC1 or TSC2, which disrupts the TSC1-TSC2 protein complex and results in constitutive activation of mechanistic target of rapamycin complex 1 (mTORC1). This mechanistic insight provided the rationale for mTORC1 inhibition with sirolimus, which has transformed disease management by stabilizing lung function and reducing disease burden in many patients. In parallel, serum vascular endothelial growth factor-D has emerged as a clinically useful biomarker supporting noninvasive diagnosis and the assessment of disease burden and treatment response. Yet current therapies are not curative, and LAM cells persist despite mTORC1 inhibition. Continued advances in single-cell biology, genomic studies, hormonal and metabolic regulation, mechanistic dissection of disease-cell states, immune-stromal interactions, and biomarker discovery are now reshaping LAM as a model of precision medicine for rare neoplastic diseases. These efforts may guide rational combination therapies aimed not only at controlling disease progression but also, ultimately, at eliminating persistent LAM cells.
Autor:innen und Institutionen
- Athens Medical School, National and Kapodistrian University of Athens, Attica, Greece, Athens.
- Sotiria General Hospital of Chest Diseases of Athens, 7th Pulmonary Medicine Department, Attica, Greece, Athens.
- General University Hospital "Attikon," Medical School, National and Kapodistrian University of Athens, 2nd Pulmonary Medicine Department, Attica, Greece, Athens.
- General University Hospital "Attikon," Athens Medical School, National and Kapodistrian University of Athens, 2nd Department of Radiology, Attica, Greece, Athens.
- Clinical Respiratory Physiology Centre, "Sotiria" Hospital, National and Kapodistrian University of Athens, 1st University Department of Respiratory Medicine, Attica, Greece, Athens.
- Lane Fox Clinical Respiratory Physiology Centre, Guy's and St Thomas' Hospitals NHS Trust, England, United Kingdom, London.
ORCID-Profile: Effrosyni D Manali
Zitieren
APA
Papiris, S. A., Skontzou, E., Kolilekas, L., Kallieri, M., Prountzos, S., Athanasopoulou, V., Kaltsakas, G., Spanou, M., Brountzos, E., Dinopoulos, A., Pujana, M. A., & Manali, E. D. (2026). Lymphangioleiomyomatosis: From Genetics to Management. Seminars in Respiratory and Critical Care Medicine. https://doi.org/10.1055/a-2991-9733
Vancouver
Papiris SA, Skontzou E, Kolilekas L, Kallieri M, Prountzos S, Athanasopoulou V, et al. Lymphangioleiomyomatosis: From Genetics to Management. Seminars in Respiratory and Critical Care Medicine. 2026. doi:10.1055/a-2991-9733
BibTeX
@article{Papiris2026,
author = {Papiris, Spyros A and Skontzou, Eirini and Kolilekas, Lykourgos and Kallieri, Maria and Prountzos, Spyridon and Athanasopoulou, Vasiliki and Kaltsakas, Georgios and Spanou, Maria and Brountzos, Elias and Dinopoulos, Argyrios and Pujana, Miquel Angel and Manali, Effrosyni D},
title = {Lymphangioleiomyomatosis: From Genetics to Management},
journal = {Seminars in Respiratory and Critical Care Medicine},
year = {2026},
doi = {10.1055/a-2991-9733}
}
EUVIMED